Glenmark Pharma gets USFDA nod for Icatibant injection
By
IANS
|
0 Views
Glenmark launches nasal spray for allergic rhinitis in India. Image Source: IANS News
Chennai, May 24 : Pharma major Glenmark Pharmaceuticals Limited on Monday said it has received the final approval from the United States Food & Drug Administration (USFDA) for Icatibant Injection, 30 mg/3 mL (10 mg/mL) Single-Dose Prefilled Syringe.
The injection is the generic version of Firazyr Injection, 30 mg/3 mL (10 mg/mL) Single-Dose Prefilled Syringe, of Shire Human Genetic Therapies, Inc.
According to Glenmark, this is the company's first synthetic decapeptide injectable approval and will be manufactured in their North American manufacturing facility based in Monroe, North Carolina.